This trial is active, not recruiting.

Condition type 2 diabetes.
Treatment the initial assessment of daily insulin dose.
Sponsor RenJi Hospital
Start date March 2012
End date May 2014
Trial size 65 participants
Trial identifier NCT02143440, 2012273


To investigate the daily dose of insulin in newly diagnosed Chinese type 2 diabetic patients who use the continuous subcutaneous insulin infusion (CSII) as the initial therapy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
The initial assessment of daily insulin dose.
the initial assessment of daily insulin dose.

Primary Outcomes

When the glucose level decreased to about 10 mmol/L
time frame: 72-96 hours

Eligibility Criteria

Male or female participants from 30 years up to 70 years old.

Inclusion Criteria: All participants with type 2 diabetes, diagnosed by World Health Organization criteria, were recruited from outpatient of the Endocrinology Department in Shanghai Renji Hospital. Exclusion Criteria: Patients who had a history of coronary heart disease, abnormal renal function, active liver disease, chronic metabolic acidosis (including diabetic ketoacidosis), or severe chronic gastrointestinal disease.

Additional Information

Official title The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by RenJi Hospital.